Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Receivables - Net (2021 - 2025)

Historic Receivables - Net for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to $343469.0.

  • InMed Pharmaceuticals' Receivables - Net rose 2064.45% to $343469.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $343469.0, marking a year-over-year increase of 2064.45%. This contributed to the annual value of $2.0 million for FY2025, which is 45333.13% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Receivables - Net is $343469.0, which was up 2064.45% from $465104.0 recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Receivables - Net registered a high of $465104.0 during Q2 2025, and its lowest value of $14842.0 during Q3 2021.
  • For the 5-year period, InMed Pharmaceuticals' Receivables - Net averaged around $194851.7, with its median value being $170299.0 (2023).
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 99334.83% in 2023, then plummeted by 2958.16% in 2024.
  • Over the past 5 years, InMed Pharmaceuticals' Receivables - Net (Quarter) stood at $50304.0 in 2021, then skyrocketed by 62.31% to $81647.0 in 2022, then skyrocketed by 356.69% to $372870.0 in 2023, then decreased by 29.58% to $262569.0 in 2024, then soared by 30.81% to $343469.0 in 2025.
  • Its Receivables - Net was $343469.0 in Q3 2025, compared to $465104.0 in Q2 2025 and $367813.0 in Q1 2025.